Characteristics of patients with non-infectious uveitis refractory to adalimumab treatment
Accept poster if oral is not possible ?
Yes
Purpose
To investigate the frequency and characteristics of non-responders to adalimumab for the treatment of non-infectious uveitis (NIU)
Methods
Twenty-five patients with NIU who followed at the JCHO Osaka Hospital for at least 6 months were studied. Changes in steroid and/or immunosuppressive therapy (IMT) and ophthalmic examinations, including anterior chamber cell grade, vitreous haze grade, optical coherence tomography (OCT) findings, and FA findings, were evaluated. Non-responders were defined as patients who showed no improvement in inflammation and for whom the prednisolone dosage could not be reduced.
Results
Five patients (20.0%) were identified as non-responders. Ocular inflammation worsened in four patients, and one patient neither achieved an improvement of ocular inflammation nor reduction in the prednisolone dosage. Non-responders were significantly older than responders (55.0 ± 9.3 years vs. 34.9 ± 12.9 years, respectively, p = 0.003). The mean corticosteroid dose at adalimumab initiation did not differ between the groups (16.0 ± 4.0 mg vs. 10.9 ± 2.1 mg, respectively). However, the ratio of the patients who received IMT as well as prednisolone was higher in responders than in non-responders. Fourteen responders (70.0%) and no non-responders received concomitant IMT at adalimumab initiation.
Conclusion
Adalimumab was not effective for 20% of the NIU patients. Our study shows that elderly NIU patients and NIU patients treated with corticosteroid alone may not respond to the adalimumab treatment.
Conflict of interest
No
Author 1
Last name
IWAHASHI
Initials of first name(s)
C
Department
Ophthalmology
City
Osakasayama
Country
Japan
Author 2
Last name
OHGURO
Initials of first name(s)
N
Department
Ophthalmology
City
Osaka
Country
Japan
Author 3
Last name
KAWA
Initials of first name(s)
T
Department
Ophthalmology
City
Osaka
Country
Japan
This website uses cookies to ensure you get the best experience on our website.
Learn more